UB Paderborn / Katalog / Suche / in CDI

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)

European journal of cancer (1990), 2018-05, Vol.94, p.79-86

2018

Volltextzugriff (PDF)

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

International journal of gynecological cancer, 2005-09, Vol.15 (5), p.679-691

2005

Volltextzugriff (PDF)

Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3084-3092

2000

Volltextzugriff (PDF)

Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study

Annals of oncology, 1996-04, Vol.7 (4), p.361-364

1996

Volltextzugriff (PDF)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

British journal of cancer, 2001-05, Vol.84 (10), p.1301-1307

2001

Volltextzugriff (PDF)

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up

Scandinavian journal of clinical and laboratory investigation, 2002, Vol.62 (3), p.177-188

2002

Volltextzugriff (PDF)

Tumor markers in the management of patients with ovarian cancer

Cancer Treatment Reviews, 1995-05, Vol.21 (3), p.215-245

1995

Volltextzugriff (PDF)

Neurotoxicity secondary to antineoplastic drugs

Cancer treatment reviews, 1994-04, Vol.20 (2), p.191-214

1994

Volltextzugriff (PDF)

Gemcitabine in the treatment of ovarian cancer

Annals of oncology, 1999, Vol.10, p.51-53

1999

Volltextzugriff (PDF)

Assessment of Biological Variation and Analytical Imprecision of CA 125, CEA, and TPA in Relation to Monitoring of Ovarian Cancer

Gynecologic oncology, 1999-07, Vol.74 (1), p.12-22

1999

Volltextzugriff (PDF)

The role of second-look laparotomy in the long-term survival in ovarian cancer

Annals of oncology, 1997-07, Vol.8 (7), p.643-648

1997

Volltextzugriff (PDF)

Advanced epithelial ovarian cancer : 1998 consensus statements

Annals of oncology, 1999, Vol.10, p.87-92

1999

Volltextzugriff (PDF)

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer

Scandinavian journal of clinical and laboratory investigation, 2000, Vol.60 (8), p.713-721

2000

Volltextzugriff (PDF)

Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Biological Variation in the Monitoring of Ovarian Cancer

Clinical chemistry and laboratory medicine, 2001-06, Vol.39 (6), p.531-538

2001

Volltextzugriff (PDF)

Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis

Seminars in oncology, 1997-10, Vol.24 (5 Suppl 15), p.S15

1997

Volltextzugriff (PDF)

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

International journal of gynecological cancer, 2005-09, Vol.15 (5), p.679-691

2005

Volltextzugriff (PDF)

Cancer épithélial de l'ovaire (stades évolués) : conférence de consensus (1998)

Gynécologie, obstétrique & fertilité, 2000, Vol.28 (7-8), p.576-583

2000

Volltextzugriff (PDF)

Abstract S6-03: DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S6-S6-03

2017

Volltextzugriff (PDF)

Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease

International journal of gynecological cancer, 1997-05, Vol.7 (3), p.213-217

1997

Volltextzugriff (PDF)

Second-look laparotomy in the management of patients after radical surgery for ovarian cancer

Annals of oncology, 1993-02, Vol.4 (2), p.169-171

1993

Volltextzugriff (PDF)

Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer

Ugeskrift for læger, 2007-01, Vol.169 (4), p.297

2007

Volltextzugriff (PDF)

TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.6072

2009

Volltextzugriff (PDF)

TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib

31st Annual San Antonio Breast Cancer Symposium,2008-12-10 - 2008-12-14, 2009, Vol.69 (2), p.368

2009

Volltextzugriff (PDF)

Taxans in the treatment of ovarian cancer

Ugeskrift for læger, 1996-07, Vol.158 (27), p.3951

1996

Volltextzugriff (PDF)

Localized nodular myositis--a focal form of myositis

Ugeskrift for læger, 1993-08, Vol.155 (34), p.2635

Tuxen, M K

1993

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer

Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up

Tumor markers in the management of patients with ovarian cancer

Neurotoxicity secondary to antineoplastic drugs

Gemcitabine in the treatment of ovarian cancer

Assessment of Biological Variation and Analytical Imprecision of CA 125, CEA, and TPA in Relation to Monitoring of Ovarian Cancer

The role of second-look laparotomy in the long-term survival in ovarian cancer

Advanced epithelial ovarian cancer : 1998 consensus statements

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer

Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Biological Variation in the Monitoring of Ovarian Cancer

Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

Cancer épithélial de l'ovaire (stades évolués) : conférence de consensus (1998)

Abstract S6-03: DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease

Second-look laparotomy in the management of patients after radical surgery for ovarian cancer

Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer

TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib

TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib

Taxans in the treatment of ovarian cancer

Localized nodular myositis--a focal form of myositis

Suchergebnisse filtern